RecruitingNot Applicable

China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes

China20,000 participantsStarted 2022-01-01

Plain-language summary

The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset \<= 20 years. CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of type 1 diabetes by a specialist
✓. Age at onset \< 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide \< 200 pmol/L
✓. Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset \<= 20 years, regardless of type and duration of disease.

What they're measuring

Change in serum hemoglobin A1c level

Timeframe: Every year for up to 10 years

Albumin-to-creatinine ratio in urine sample

Timeframe: up to 10 years

Arteriosclerotic cardiovascular diseases

Timeframe: up to 10 years

Electromyography

Timeframe: up to 10 years

PHQ-9

Timeframe: up to 10 years

GAD-7

Timeframe: up to 10 years

WHO-5

Timeframe: up to 10 years

PAID

Timeframe: up to 10 years

Trial details

NCT IDNCT05498974

SponsorSecond Xiangya Hospital of Central South University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2035-12-31

Contact for this trial

Zhiguang Zhou, MD, PhD

+8673185292154 zhouzhiguang@csu.edu.cn

View on ClinicalTrials.gov More Type1diabetes trials